Key Drivers
- Strong margins
- Weak liquidity
- Rich valuation
AIAI Summary
AZN should be viewed less as a defensive pharma holding and more as a premium-valued pipeline execution story: strong cash flow and margins support the thesis, but the stock likely needs multiple successful Phase III/readout wins and cleaner regulatory outcomes to justify upside, while further pipeline misses or FDA setbacks could keep shares under pressure.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Strong margins
- •Weak liquidity
- •Rich valuation
AZN delivered strong, cash-backed profitability and solid interest coverage, but weak liquidity, elevated leverage, and a rich valuation limit upside.
Price Behavior
Key Price Behavior Insights:
- •Lower highs
- •Repeated resistance
- •Near-term support
AZN has been in a clear downtrend over the last month, with repeated failures near $185–$188 and near-term support around $181–$182, keeping the short-term outlook bearish unless price reclaims resistance. క
Sharp drop from $204.80 to $181.58 over the last month suggests elevated downside pressure
Sentiment & News
Key News Insights:
- •Revenue growth
- •Pipeline catalysts
- •FDA setback
AstraZeneca posted strong Q1 growth and reaffirmed 2026 guidance, but the stock's upside is tempered by a recent FDA advisory setback for camizestrant despite a robust second-half pipeline.
The news is modestly positive overall for AstraZeneca, with strong operating momentum and pipeline depth outweighing near-term regulatory risk
Similar Companies in Healthcare
Other companies in the same sector with AI ratings